Caitong International Asset Management’s Entrada Therapeutics TRDA Stock Holding History

Caitong International Asset Management’s Portfolio TRDA Stock Details TRDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339	Buy	+46	New	+$441	﹤0.01%	1862

Other funds holding TRDA

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Caitong International Asset Management's TRDA Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 46 shares worth $339. The stake represents ﹤0.01% of the portfolio and ranks #1862 among its holdings.

129 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

Caitong International Asset Management held 46 shares of Entrada Therapeutics worth $339 as of Q2 2026.
Entrada Therapeutics was a new Caitong International Asset Management position in Q2 2026.
Entrada Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1862 holding.
129 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.